A self-illuminating nanoparticle for inflammation imaging and cancer therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30662940.
- Also identified by DOI 10.1126/sciadv.aat2953 and PMC identifier 6326751.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nanoparticles have been extensively used for inflammation imaging and photodynamic therapy of cancer. However, the major translational barriers to most nanoparticle-based imaging and therapy applications are the limited depth of tissue penetration, inevitable requirement of external irradiation, and poor biocompatibility of the nanoparticles. To overcome these critical limitations, we synthesized a sensitive, specific, biodegradable luminescent nanoparticle that is self-assembled from an amphiphilic polymeric conjugate with a luminescent donor (luminol) and a fluorescent acceptor [chlorin e6 (Ce6)] for in vivo luminescence imaging and photodynamic therapy in deep tissues. Mechanistically, reactive oxygen species (ROS) and myeloperoxidase generated in inflammatory sites or the tumor microenvironment trigger bioluminescence resonance energy transfer and the production of singlet oxygen (<sup>1</sup>O<sub>2</sub>) from the nanoparticle, enabling in vivo imaging and cancer therapy, respectively. This self-illuminating nanoparticle shows an excellent in vivo imaging capability with suitable tissue penetration and resolution in diverse animal models of inflammation. It is also proven to be a selective, potent, and safe antitumor nanomedicine that specifically kills cancer cells via in situ <sup>1</sup>O<sub>2</sub> produced in the tumor microenvironment, which contains a high level of ROS.
Medical subject headings
- Antineoplastic Agents
- Luminescent Agents
- Nanoparticles
- Neoplasms
- Photochemotherapy
- Theranostic Nanomedicine